Ghent, Belgium – 1 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces the grant of an additional US patent for its DSR (Direct Sodium Removal) program. Read more…
Dr. Gericke brings extensive experience in the research and development of radioligand therapies Appointment coincides with launch of Ariceum International AG in Basel, Switzerland Berlin, Germany, 1 February 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, is pleased to announce […]
Newly appointed CFO with significant experience in medical technology and public / private financing Insulin Pump system Kaleido to expand commercial roll out in Europe February 1, Utrecht, The Netherlands ViCentra B.V., the company behind Kaleido, one of the world’s smallest, lightest and most precise Insulin Pump systems for treating people with type 1 Diabetes, is pleased to […]
Düsseldorf and Barcelona – February 1, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the closing of the previously announced acquisition of two established product portfolios for CNS disorders, pain and vascular diseases from Sanofi. Read more…
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, announces that its partner, Cooper Consumer Health (“Cooper”) has initiated pre-launch activities ahead of the launch of MED3000 (Eroxon™), Futura’s breakthrough, topical gel formulation for the treatment of erectile […]
